ImmunoGen, Inc. Announces Webcast of Presentation at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN) announced today that the company will present at two investor conferences in the next two weeks. These presentations will be webcast live and can be accessed through the “Investor Information” section of the Company’s website, www.immunogen.com. An archive of these webcasts will be available at the same location until August 20, 2010.

  • BMO Capital 10th Annual Focus on Healthcare Conference
    Thursday, August 5, 2010 at 10:15 a.m. ET
    New York, NY
  • Canaccord/Genuity 30th Annual Growth Conference 2010
    Thursday, August 12, 2010 at 9:30 a.m. ET
    Boston, MA

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cancer-cell killing agents. The Company’s Targeted Antibody Payload (TAP) technology uses engineered antibodies to deliver one of ImmunoGen’s proprietary cancer-cell killing agents specifically to tumor targets. In addition to the Company’s product pipeline, compounds are in clinical testing through ImmunoGen’s collaborations with Genentech (a member of the Roche Group), sanofi-aventis, Biogen Idec and Biotest. A marketing application for the most advanced compound using ImmunoGen’s TAP technology, T-DM1, was submitted to the US FDA by Genentech in July 2010. Other ImmunoGen collaborative partners include Bayer Schering Pharma AG and Amgen. More information about ImmunoGen can be found at www.immunogen.com.



CONTACT:

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
[email protected]
or
For Media:
The Yates Network
Adriana Jenkins, 617-744-1713

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Other Health  Research  Science

MEDIA:

Suggested Articles

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."

F2G has raised $60.8 million to fund late-phase clinical development of its antifungal agent olorofim and prepare for commercialization.

Combining an anti-TREM2 antibody with an immuno-oncology drug that blocks PD-1 led to complete tumor control in a mouse study.